NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cue Biopharma, Inc. Common Stock (CUE) Stock Analysis

Cue Biopharma, Inc. Common Stock (CUE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CUE

$18.95

+$1.91 (+11.21%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CUE with… →

CUE Key Statistics

As of Oct 21, 2026
Trading
Open
$17.28
Previous Close
$17.04
Day's Range
17.28–19.54
52-Week Range
4.98–45.50
Volume
112.18K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.63
Valuation
Market Cap
$137.66M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−29.59
Financials (FY)
Revenue (FY)
$27.47M+195.75%
Net Income (FY)
−$26.60M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.26M
1-Year Return
−23.43%
Dividend and dates
Avg Volume
273.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CUE closed at $18.95, −23.43% over 1 year.

Cue Biopharma, Inc. Common Stock (CUE) has a market capitalization of $137.66M.

In fiscal 2025, CUE reported revenue of $27.47M.

CUE Stock Return by Calendar Year

Cue Biopharma, Inc. Common Stock (CUE) return since Jan 2018: what $10,000 became

1 year
$10,000 $7,657
−23.43%
5 years
$10,000 $516
−94.84%
Since Jan 2018
$10,000 $543
−94.57%

If you had invested $10,000 in Cue Biopharma, Inc. Common Stock (CUE) at the close on January 2, 2018, the earliest close on record here, it would have been worth $543 at the close on October 21, 2026: −94.57% in total, −28.18% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+107.10%
2025−72.02%
2024−58.71%
2023−7.37%
2022−74.80%
2021−9.59%
2020−21.20%
2019+237.77%
2018−59.59%

As of October 21, 2026.

CUE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$27.47M−$26.60M−96.9%
2024$9.29M−$40.67M−438.0%
2023$5.49M−$50.73M−924.1%
2022$1.25M−$53.01M−4,257.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$27.47M—−$26.52M−$26.60M−96.9%
2024$9.29M—−$41.59M−$40.67M−438.0%
2023$5.49M—−$51.99M−$50.73M−924.1%
2022$1.25M—−$53.50M−$53.01M−4,257.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CUE Valuation vs Biotechnology Median

Median of 608 stocks
MetricCUEBiotechnology medianvs median
P/S ratio3.6613.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cue Biopharma, Inc. Common Stock (CUE) is capitalised at $137.66M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 29.

CUE last closed at $18.95 on October 21, 2026. That is +$1.91 (+11.21%) against the previous close. The 52-week range on file runs from $4.98 to $45.50. The latest close sits 280.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $27.47M. Against the prior fiscal year total of $9.29M, that is a change of +195.75%. The same year closed with a net loss of $26.60M. Earnings per share on a trailing basis come to −29.59.

Across the 4 fiscal years on file, revenue moves from $1.25M in 2022 to $27.47M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.66. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −23.43%. Across 5 years the annualized return works out at −44.71%. Beta against the wider market is reported at 2.63. Daily returns over the trailing 8 years annualize to a volatility of 109.83%.

Growth & Income

No dividend is on file for CUE.

So far in 2026 the total return is +107.10%. The strongest complete calendar year on file is 2019 at +237.77%; the weakest is 2022 at −74.80%. Of the 8 complete calendar years on file, 1 finished higher.

Peer Comparison

Cue Biopharma, Inc. Common Stock (CUE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cue Biopharma, Inc. Common Stock CUE $137.66M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cue Biopharma, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cue Biopharma, Inc. Common Stock

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Visit website →